Overview

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged 40 to 85 Years With Chronic Obstructive Pulmonary Disease.

Status:
RECRUITING

Trial end date:
2029-02-15

Target enrollment:

Participant gender:

Summary

LPS18583 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 4 study with 2 treatment groups. The purpose of this study is to assess the effect of dupilumab compared with placebo on airway inflammation, resistance, and remodeling including mucus plugging and its association with improvement on lung function, exacerbations, and quality of life improvement in participants aged 40 years of age up to 85 years of age (inclusive). Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The number of visits will be 9.

Phase:

PHASE4

Details

Lead Sponsor:

Sanofi

Collaborator:

Regeneron Pharmaceuticals

Treatments:

dupilumab